Stroke, ischemic (ISTK); This literature-non-study case was reported in a literature article and describes the occurrence of ISCHAEMIC STROKE (Stroke, ischemic (ISTK)) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.       No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ISCHAEMIC STROKE (Stroke, ischemic (ISTK)) (seriousness criterion medically significant). At the time of the report, ISCHAEMIC STROKE (Stroke, ischemic (ISTK)) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medications were not reported. This case refers to a patient of unknown age and gender who experienced the Ischemic stroke first dose of mRNA-1273 vaccine.   This study described simultaneous vaccination (SV) with primary series COVID-19 vaccines and assess 23 pre-specified health outcomes following SV among persons aged greater than or equal to 5 years in the Vaccine Safety Datalink (VSD). from December 11, 2020-May 21, 2022. Analyses assessed frequency of SV.   Rate ratios (RRs) were estimated by Poisson regression when the number of outcomes was greater than or equal to 5 across both doses, comparing outcome rates between COVID-19 vaccinees receiving SV and COVID-19 vaccinees receiving no SV in the 1-21 days following COVID-19 vaccine dose 1 and 1-42 days following dose 2 by SV type received.  The most frequent simultaneous vaccines were influenza, HPV, Tdap, and meningococcal. Outcomes following SV with COVID-19 vaccines were rare (total of 56 outcomes observed after dose 1 and dose 2). Overall rate of outcomes among COVID-19 vaccinees who received SV was not statistically significantly different than the rate among those who did not receive SV.  The most frequent simultaneous vaccines were influenza, HPV, Tdap, and meningococcal. Outcomes following SV with COVID-19 vaccines were rare (total of 56 outcomes observed after dose 1 and dose 2). Overall rate of outcomes among COVID-19 vaccines who received SV was not statistically significantly different than the rate among those who did not receive SV.   This case was linked to US-MODERNATX, INC.-MOD-2023-731103 (Linked Report).  Company comment :This is a Literature-Non-Study case concerning a patient with no reported  age, gender, nor medical history, who experienced the unexpected serious (medically significant) AESI of Ischaemic stroke. The event occurred between 1-21 days after the administration of the first dose of mRNA-1273 vaccine, however exact latency could not be assessed due to lack of information.  No further information on clinical course, investigations and treatment received was available in the report. More information is requested. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a Literature-Non-Study case concerning a patient with no reported  age, gender, nor medical history, who experienced the unexpected serious (medically significant) AESI of Ischaemic stroke. The event occurred between 1-21 days after the administration of the first dose of mRNA-1273 vaccine, however exact latency could not be assessed due to lack of information.  No further information on clinical course, investigations and treatment received was available in the report. More information is requested. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. US-MODERNATX, INC.-MOD-2023-731103:Patinet with appendicitis after first dose( Master case)